TP53 alterations have been described in small cell lung carcinoma (>90%),6 squamous cell carcinoma (81%),8, 9 and lung adenocarcinomas (40%–46%), chiefly in association with other driver mutations and in current or former smokers.8, 9. Here, TP53 is linked to lung adenocarcinoma.